Table 2.
SARS-CoV-2 neutralizing antibody responses in serum following single or double intranasal administration of candidate vaccine BBV154. .
| Animal Model | Dose (VP/animal) | Neutralizing Antibody Titers (MNT50)(mean) | |
|---|---|---|---|
| Prime | Booster | ||
| BALB/c Mice | Placebo | 7.6 ± 2.6 | 6.7 ± 1.3 |
| 5x109 | 7.8 ± 4.0 | 45.8 ± 78.3 | |
| 5x1010 | 76.6 ± 68.8 | 120.9 ± 97.8 | |
| 5x1011 | 264.8 ± 347.3 | 454.1 ± 356.9 | |
| Swiss Albino Mice | Placebo | 8.6 ± 3.2 | 7.2 ± 3.5 |
| 5x109 | 13.9 ± 7.7 | 111.9 ± 111.6 | |
| 5x1010 | 146.6 ± 181.7 | 359.5 ± 366.8 | |
| 5x1011 | 325.1 ± 217.0 | 741.1 ± 434.5 | |
| Wistar Rats | Placebo | 5.7 ± 0.4 | 7.4 ± 1.7 |
| 5x109 | 17.3 ± 31.8 | 16.7 ± 23.4 | |
| 5x1010 | 158.9 ± 208.5 | 128.2 ± 231.4 | |
| 5x1011 | 278.3 ± 338.0 | 545.2 ± 503.8 | |
| New Zealand Rabbit* | Placebo | 5.7 ± 0.0 | 5.7 ± 0.0 |
| 5x109 | 5.7 ± 0.0 | 5.7 ± 0.0 | |
| 5x1010 | 12.4 ± 11.9 | 9.5 ± 9.4 | |
| 5x1011 | 23.9 ± 26.0 | 26.5 ± 41.4 | |
Each group consisting of 10–12 animals; *Consisting of 4–6 animals; Limit of detection-5.6.